Together we will beat cancer

Donate

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

Read More

Three new cancer drugs approved for NHS in Scotland

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

Read More

NICE approves new maintenance treatment for ovarian cancer

A new targeted treatment has been recommended by the National Institute of Health and Care Excellence for some adults with ovarian cancer.

Read More

Scottish Medicines Consortium says yes to chemotherapy-free leukaemia treatment

The Scottish Medicines Consortium (SMC) has approved a new chemotherapy-free treatment option for some adults with untreated chronic lymphocytic leukaemia.

Read More

First ‘targeted’ bowel cancer treatment combo approved for NHS use in England 

The first chemotherapy-free drug combination for people with a rare type of bowel cancer has been approved for NHS use in England.  

Read More

Chemotherapy free treatment for leukaemia given the green light for NHS in England

A new combination of targeted treatments will now be available for some adults with leukaemia on the NHS in England.

Read More

Rare bowel cancer treatment combo gets initial no for NHS use in England  

A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence.

Read More

Non-Hodgkin lymphoma treatment gets the green light for NHS use in England 

The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.

Read More

Targeted treatment for leukaemia approved on NHS in England 

The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.  

Read More

Targeted drug improves survival for children with non-Hodgkin lymphoma

New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.

Read More